Results 41 to 50 of about 111,950 (304)

Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer

Breast Cancer: Targets and Therapy, 2023
Hikmat Abdel-Razeq,1,2 Lama Abujamous,3 Khansa Al-Azzam,1 Hala Abu-Fares,1 Hira Bani Hani,1 Mais Alkyam,1 Baha’ Sharaf,1 Shatha Elemian,1 Faris Tamimi,1 Fawzi Abuhijla,4 Sarah Edaily,1 Osama Salama,1 Hazem Abdulelah,1 Rand Daoud,1 Mohammad Abubaker,1 ...
Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A   +15 more
doaj  

BRCA1 A-Complex fine tunes repair functions of BRCA1

Aging, 2011
Germline mutations in BRCA1 increase the risk of breast and ovarian cancer, but the specific pathways driving breast and ovarian cancer development in BRCA1 mutants are currently unclear [1]. Several studies have demonstrated that BRCA1 is required for cellular responses to DNA double strand breaks (DSBs) and homologous recombination (HR), although its
Janelle L, Harris, Kum Kum, Khanna
openaire   +2 more sources

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) [PDF]

, 2003
INTRODUCTION: Ancestral mutations in BRCA1 and BRCA2 are common in people of Ashkenazi Jewish descent and are associated with a substantially increased risk of breast and ovarian cancer.
Ellen Solomon, Fisher, S A, Lewis, C M; id_orcid, Lewis, CM, Southey, MC, John L Hopper, Hodgson, SV, Venter, DJ, Michael Friedlander, Hopper, JL, Hopper, J L, Solomon, E, Bankier, A, Hooper, J L, Cathryn M Lewis, Tucker, K, Melissa C Southey, Southey, M C, Lesley Andrews, Friedlander, M, Carmel Apicella, Hodgson, S V, Fisher, SA, Katherine Tucker, Venter, D J, Agnes Bankier, Apicella, C, Deon J Venter, Andrews, L, Shirley V Hodgson, Sheila A Fisher   +30 more
core   +2 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Effect of BRCA1 R1325K mutation on proliferation and apoptosis of gallbladder cancer cells

Shanghai Jiaotong Daxue xuebao. Yixue ban, 2023
Objective·To investigate the effects of breast cancer susceptibility gene 1 (BRCA1) R1325K mutation [arginine (R) to lysine (K) mutation at amino acid 1325] on the proliferation and apoptosis of gallbladder cancer cell lines GBC-SD and NOZ.Methods·BRCA1 ...
YANG Jingxiao, JIA Ziyao, WU Wenguang, WU Xiangsong, ZHANG Fei, LI Huaifeng, ZHU Yidi, LI Maolan   +7 more
doaj   +1 more source

BRCA1-Mediated Ubiquitylation [PDF]

Cell Cycle, 2006
The BRCA1 tumour suppressor and its heterodimeric partner BARD1 play crucial roles in coordinating cellular responses to DNA damage. Evidence also implicates these proteins in transcriptional regulation, cell cycle progression and meiotic sex chromosome inactivation, but their mode of action remains elusive.
openaire   +2 more sources

Men's decision-making about predictive BRCA1/2 testing: the role of family [PDF]

, 2005
Men who have a family history of breast and/or ovarian cancer may be offered a predictive genetic test to determine whether or not they carry the family specific BRCA1/2 mutation.
Moynihan, C., R. Eeles, A. Lucassen, Eeles, R., Hallowell, N., A. Ardern‐Jones, C. Foster, Ardern-Jones, A., M. Watson, Lucassen, A., Foster, C., Watson, M., C. Moynihan, N. Hallowell   +13 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

BRCA1/2 associated cancer susceptibility: a clinical overview

Forum of Clinical Oncology, 2016
The most frequently identified genetic cause of breast cancer is the germline mutation of BRCA1 and 2 genes. The carriers of these mutations are at high risk for breast and ovarian cancers and increased risk for pancreatic and prostate cancers.
Lypas Georgios
doaj   +1 more source

Developing a community-based breast cancer risk prediction tool for resource-poor settings

Journal of Education and Health Promotion, 2019
BACKGROUND: With an estimation of every two women newly diagnosed with breast cancer, one dies. It is accounted that 1 in 28 women is likely to develop breast cancer during her lifetime.
Divya Pillai, Shaikh Shah Hossain, Vijay Kumar Chattu   +2 more
doaj   +1 more source